근긴장성 이영양증 1형(DM1) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Myotonic Dystrophy Type 1 (DM1) Market Outlook

Thelansis's "Myotonic Dystrophy Type 1 (DM1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myotonic Dystrophy Type 1 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Myotonic Dystrophy Type 1 (DM1) Overview

Myotonic Dystrophy Type 1 (DM1) is a multisystemic, autosomal dominant neuromuscular disorder caused by an unstable expansion of a CTG trinucleotide repeat in the 3' untranslated region of the DMPK gene (chromosome 19q13.3). This mutation leads to toxic RNA accumulation and widespread cellular dysfunction affecting multiple organ systems.

DM1 impacts skeletal and smooth muscle, cardiac, ocular, endocrine, and central nervous systems, making it one of the most clinically heterogeneous muscular dystrophies. Disease severity and age of onset correlate strongly with CTG repeat length.

Clinically, DM1 is classified into three phenotypes:

Mild form - cataracts, mild myotonia

Classic form - muscle weakness, myotonia, cardiac involvement

Congenital form - severe hypotonia, respiratory failure, developmental delay

Diagnosis is confirmed through molecular genetic testing, particularly in patients presenting with distal muscle weakness, myotonia, and multisystem involvement

Currently, there are no approved disease-modifying therapies, and management remains symptomatic and multidisciplinary, including cardiac monitoring, respiratory support, and supportive care.

Key Highlights

• DM1 is a rare, chronic, and progressive disorder, with a relatively stable but slowly increasing patient population.
• In Italy, the prevalent DM1 population is expected to grow modestly from 3.8K in 2025 to 4.0K by 2035, reflecting a low growth rate (0.4% CAGR).
• Increasing focus on genetic and RNA-targeted therapies is expected to reshape the future treatment paradigm.

Market Overview

• The DM1 market in Germany is projected to grow from ~$78M in 2025 to ~$245M by 2035, reflecting a strong double-digit CAGR (~12-13%), driven by pipeline innovation and emerging therapies, despite a small patient base.
• The patient population shows minimal growth (~0.4% CAGR), indicating: Stable disease prevalence & Limited impact of incidence changes on market expansion

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Avidity Biosciences, Inc.
• Lupin Ltd.
• PepGen Inc
• Sanofi
• Arrowhead Pharmaceuticals
• Dyne Therapeutics
• Vertex Pharmaceuticals Incorporated
• Harmony Biosciences Management, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)